Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026
· confo therapeutics
Source Summary
Confo Therapeutics shared promising preclinical data for CFTX-2034, a potential first-in-class treatment for post-bariatric hypoglycemia, at ENDO 2026.
Advertisement